Insmed
Open
$95.63
Prev. Close
$95.70
High
$95.74
Low
$95.25
Market Snapshot
$20.59B
-17.4
-5.57
$363.71M
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,664 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Insmed's recent stock decline follows impressive three-year growth from its rare disease drugs, highlighting ongoing challenges in maintaining market confidence despite product successes.
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,664 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Recently from Cashu
Insmed Navigates Investor Changes Amid Strong Pipeline and Mixed Analyst Sentiment
Insmed Inc (Ticker: INSM) is in a transformative phase as it navigates recent changes in its investor landscape and the impact on its business model. The company, known for its focus on rare diseases,…
Insmed's Brensocatib Launch Receives Positive Feedback Amid Stock Performance Challenges
Insmed Inc. (Ticker: INSM) is experiencing significant excitement around its newly launched medication, brensocatib, due to encouraging feedback from physicians. The early responses suggest a broad pr…
Insmed Expands Workforce and Advances Promising Clinical Trials in Biopharmaceuticals
Insmed Incorporated (Ticker: INSM) continues to solidify its presence in the biopharmaceuticals sector through strategic hiring and promising clinical trial results. Recently, the company announced th…
Insmed Implements Financial Strategy to Enhance Operations Amid Insider Trading Speculations
Insmed (Ticker: INSM) is navigating strategic financial adjustments to bolster its operations. Recently, the company has filed an automatic shelf registration, aiming to issue common stock and debt se…